Abstract
Abstract
Background: Polycystic ovary syndrome (PCOS) is a common reproductive endocrine disorder, which is characterized by insulin resistance (IR) and menstrual cycle disorders. IR is thought of as a pivotal cause of PCOS and related comorbidities. However, the link between IR and abnormal menstrual cycles in PCOS should be further studied. In this study, we aimed to clarify the dose-response relationship between IR and abnormal menstrual cycles in patients with PCOS.
Results: In this retrospective study including140 patients with PCOS, we found that there was a dose-response relationship between the increased HOMA-IR index and the level of menstrual cycle disorders (1.610 [95%CI: 1.37-1.85] for normal menstruation, 2.020 [95%CI: 1.61-2.44] for oligomenorrhea, 2.350 [95%CI:1.96-2.75] for amenorrhea, Pfor trend = 0.003). Further stratification analyses showed that this dose-response relationship was more evident in the patients who were younger than 25 years, had higher AFC numbers and had elevated levels of testosterone, anti-Müllerian hormone, inhibin B, and prolactin levels.
Conclusions: Our study has established an association between IR and abnormal menstrual cycles in patients with PCOS, which can be affected by age and aberrant hormone levels. Our results might be helpful for further prevention and treatment of amenorrhea in PCOS.
Publisher
Research Square Platform LLC
Reference49 articles.
1. Hyperandrogenism and menstrual imbalance are the best predictors of metformin response in PCOS patients;Garzia E;Reprod Biol Endocrinol,2022
2. Epidemiology, diagnosis, and management of polycystic ovary syndrome;Sirmans SM;Clin Epidemiol,2013
3. Association between Biomarkers of Low-grade Inflammation and Sex Hormones in Women with Polycystic Ovary Syndrome;Hatziagelaki E;Exp Clin Endocrinol Diabetes,2020
4. Zhang Y, Ho K, Keaton JM, Hartzel DN, Day F, Justice AE, Josyula NS, Pendergrass SA, Actkins K, Davis LK, et al: A genome-wide association study of polycystic ovary syndrome identified from electronic health records. Am J Obstet Gynecol 2020, 223(4):559.e551-559.e521.
5. Administration of a VIP-antagonist in vivo modifies ovarian hormone secretion in a rat model with polycystic ovary syndrome;Morales-Ledesma L;Life Sci,2021